Navigation Links
If The World Wide Web is Your Self Proclaimed Physician, Trouble Could be Just a Click Away

The internet which is a reservoir of information has done unimaginable wonders to industries and society.// In a society that is largely technology driven, ‘net’ working is the byword of the present age, with information available with a mere tap of the fingers. Therefore it comes as no surprise that the internet is being rummaged for solutions on several matters, even life and death issues pertaining to health.

While acknowledging that it is important to be well informed and aware about health issues, in order to take informed decisions, a recent study published in the Journal Chest has found that most patients diagnosed with lung cancer resorted to the internet for information regarding treatment strategies. The internet figured the first, above all other likely options - for instance speaking to family or friends, referring to medical journals, magazines, television, checking from medical libraries, as an information source.

Take the case of a 64-year-old woman whose story had been published by the medical journal Lancet. She had diagnosed herself with chronic fatigue syndrome and then used the internet to self-medicate with oral steroids which she procured over the internet. She had been altering the dosage herself over a four year period. The steroid use led to serious cataract in both the eyes and glaucoma, which are side effects that physicians are well aware of, but was not known to this lady.

Medicines purchased over the internet have no quality checks and may not impact the user in a manner that it claims. Moreover the drugs may have serious often irrevocable side effects which are seldom known to patients.

In the scenario, readers must use their discretion to sift authentic information and patronize sites that provide reliable information. Medical Journals of repute which have been in the business for many years have a standard review process, where other medical doctors actually evaluate and ratify the informa
'"/>




Page: 1 2

Related medicine news :

1. The World Bank funds private Hospital in India
2. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
3. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
4. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
5. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
6. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
7. World SARS-free within weeks
8. Worlds oldest turns 116 in Japan
9. Does Success in School Differ From the Real World Success ?
10. Benefits Of The Worlds Most Widely Used Beverage
11. Chennai Plays Hosts To The Diabetes World Congress
Post Your Comments:
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 1SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 2SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 3SAFC Pharma 28R 29 Announces Completion of 2412M Contract Manufacturing Facility Expansion in Carlsbad Calif 5412 4Studying cancer in pet dogs to find new treatments for human patients 59325 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 1Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 2Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 3Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 4Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 5Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 6Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 7Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt 28TM 29 in the U S and Canada fo 5409 8